"EuBiologics expected to rebound in Q3 earnings"
Predicted impact: Low
Analyst expects Q3 rebound; forecast only, no reported figures.
EuBiologics유바이오로직스
206650 · KOSDAQ · ₩206650 · 유바이오로직스
₩7,460▲ ₩130 (1.77%)End-of-day · Oct 26, 2026 · End-of-day prices.
Price · 1Y −42.35%
DCA3 ₩8,070STOP ₩8,020DCA2 ₩7,890DCA1 ₩7,720Entry ₩7,540TP1 ₩7,190TP2 ₩6,840TP3 ₩6,310TP4 ₩5,780
Entry, trailing stop, targets and DCA levels of the current Squeeze! setup (paper-trading levels from a fixed rule, not advice).
- Market cap
- ₩271B
- Enterprise value
- ₩222B
- P/E
- 9.3×
- P/B
- 1.5×
- Dividend yield
- 0.0%
- ROE
- 16.0%
- Net margin
- 23.7%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−57.9% from the high
₩6,950Today: ₩7,210 – ₩7,540₩17,700
Returns
- 1W−7.6%
- 1M−9.5%
- 3M−7.6%
- 6M−45.2%
- YTD−34.3%
- 1Y−41.4%
- Volume today
- 168,048
- 1.5× the 20-day average
- Traded today
- ₩1.2B
- Listed shares
- 36,353,320
- EPS (12 months)
- ₩798
- Earnings yield 10.7%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 51 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: A large new supply deal and an expected earnings rebound are positive, though the sources give no detail beyond headlines. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-10.9% over the last month; the price is below its 20-day average.
- News impactSome7 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
EuBiologics stock overview
EuBiologics (유바이오로직스, KRX: 206650) is listed on KOSDAQ, in the Biotech & Pharma sector. Korean vaccine company founded in March 2010, headquartered in Seoul's Gangnam District, with plants and an in-house research institute in Chuncheon. Its shares closed at ₩7,460 on Oct 26, 2026, up 1.77% on the day, giving it a market value of ₩271B.
Key facts
- Market cap
- ₩271B
- Sector
- Biotech & Pharma
- Latest price change
- +1.77%
- As of
- Oct 26, 2026
- Main business
- Korean vaccine company founded in March 2010, headquartered in Seoul's Gangnam District, with plants and an in-house research institute in Chuncheon.
Quick answers about EuBiologics
- What does EuBiologics do?
- Korean vaccine company founded in March 2010, headquartered in Seoul's Gangnam District, with plants and an in-house research institute in Chuncheon. It develops and supplies safe, effective vaccines, mainly an oral cholera vaccine sold largely to UNICEF for public-market buyers, with other vaccines in development. It also provides contract research and manufacturing (CRMO) services for biopharmaceuticals, and sells to overseas markets through local pharmaceutical partners.
- What is the market cap of EuBiologics?
- The market capitalisation of EuBiologics was ₩271B at the close on Oct 26, 2026.
- Who are the largest shareholders of EuBiologics?
- According to the latest official filings, the largest reported holders are BioNote (20.96%, as of Apr 7, 2026); Baek Young-ok (2.60%, as of Jan 2, 2026); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (1.12%, as of Jul 31, 2026).
- When is the next earnings report from EuBiologics?
- Korean companies rarely announce results dates in advance. Based on when EuBiologics filed the same report in past years, its next preliminary results is expected around Oct 28, 2026.
- Does the National Pension Service own EuBiologics?
- Yes. The National Pension Service held 0.17% of EuBiologics shares as of Dec 31, 2025.
Company profile
Korean vaccine company founded in March 2010, headquartered in Seoul's Gangnam District, with plants and an in-house research institute in Chuncheon. It develops and supplies safe, effective vaccines, mainly an oral cholera vaccine sold largely to UNICEF for public-market buyers, with other vaccines in development. It also provides contract research and manufacturing (CRMO) services for biopharmaceuticals, and sells to overseas markets through local pharmaceutical partners.
Written by AI from the company's latest annual report.
- Korean name
- 유바이오로직스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 백영옥,허태영(공동대표이사)
- Founded
- Mar 2010
- Listed
- Jan 2017
- Listed shares
- 36,353,320
- Fiscal year ends
- Month 12
- Website
- www.eubiologics.com
Similar companies
- Samsung Biologics207940 · ₩67T₩1,452,000−0.95%
- Celltrion068270 · ₩44T₩190,000−2.26%
- Alteogen196170 · ₩15T₩218,500−2.67%
- Yuhan000100 · ₩6T₩81,700−3.54%
- SK biopharmaceuticals326030 · ₩5.9T₩75,800−1.43%
- HLB028300 · ₩5.2T₩39,250−5.65%
- Hanmi Pharm128940 · ₩4.5T₩352,500−2.49%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,900−5.17%
Recent news
EuBiologics Signs ₩10.5B Vaccine Supply Contract with UNICEF
Predicted impact: Low
₩10.5B UNICEF contract is about 9% of last year's revenue, but near 10% threshold and modest.
WHO Director-General visits Yoobiologics, reviews global vaccine capabilities
Predicted impact: Low
WHO official visit with no immediate financial impact.
Recent filings
See all- Major sales or supply contractOct 26, 2026
- Major management matter relevant to investorsOct 21, 2026
- Major management matter relevant to investorsOct 21, 2026
- Change of Head Office LocationOct 6, 2026
- Amended: Acquisition of shares in another companyAug 26, 2026
Titles in Korean until English translations are added.
Also known as: EuBiologics / 유바이오로직스 / 206650 / KRX:206650
Source: KRX statistical information